CA2581430A1 - Compositions and methods for detecting and treating tumors - Google Patents

Compositions and methods for detecting and treating tumors Download PDF

Info

Publication number
CA2581430A1
CA2581430A1 CA002581430A CA2581430A CA2581430A1 CA 2581430 A1 CA2581430 A1 CA 2581430A1 CA 002581430 A CA002581430 A CA 002581430A CA 2581430 A CA2581430 A CA 2581430A CA 2581430 A1 CA2581430 A1 CA 2581430A1
Authority
CA
Canada
Prior art keywords
ephb4
cell
tumor
test cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002581430A
Other languages
English (en)
French (fr)
Inventor
Ramachandra Reddy
Parkash Gill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2581430A1 publication Critical patent/CA2581430A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002581430A 2004-09-23 2005-09-23 Compositions and methods for detecting and treating tumors Abandoned CA2581430A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61286104P 2004-09-23 2004-09-23
US60/612,861 2004-09-23
PCT/US2005/034179 WO2006034456A2 (en) 2004-09-23 2005-09-23 Compositions and methods for detecting and treating tumors

Publications (1)

Publication Number Publication Date
CA2581430A1 true CA2581430A1 (en) 2006-03-30

Family

ID=36090700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002581430A Abandoned CA2581430A1 (en) 2004-09-23 2005-09-23 Compositions and methods for detecting and treating tumors

Country Status (6)

Country Link
US (1) US20060194220A1 (https=)
EP (1) EP1799867A2 (https=)
JP (1) JP2008514925A (https=)
AU (1) AU2005286663A1 (https=)
CA (1) CA2581430A1 (https=)
WO (1) WO2006034456A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218061A1 (en) * 2005-09-23 2007-09-20 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
JP2008289456A (ja) * 2006-06-16 2008-12-04 Sysmex Corp がん細胞の検出方法及び装置
US7662566B2 (en) * 2006-11-22 2010-02-16 Myriad Genetics, Inc. Gene copy number profiling
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
ES2386495T3 (es) * 2007-11-29 2012-08-21 Molecular Health Gmbh siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso
JP5610125B2 (ja) * 2010-02-22 2014-10-22 国立大学法人 長崎大学 癌転移の検出方法および検出用キット
GB201616640D0 (en) * 2016-09-30 2016-11-16 Sarphie David And Mian Rubina Monitoring cancer recurrence and progression
ES2832880T3 (es) * 2017-06-08 2021-06-11 Lumito Ab Un método de análisis de una muestra para al menos un analito
US12020493B2 (en) 2018-07-27 2024-06-25 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
JP7464977B2 (ja) * 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株
EP4105328A1 (en) * 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH

Also Published As

Publication number Publication date
EP1799867A2 (en) 2007-06-27
WO2006034456A3 (en) 2006-08-10
US20060194220A1 (en) 2006-08-31
AU2005286663A1 (en) 2006-03-30
WO2006034456A2 (en) 2006-03-30
JP2008514925A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
EP3556866B1 (en) Mutations of the pik3ca gene in human cancers
EP2558490B1 (en) Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors
EP0821733B1 (en) Genetic markers for breast and ovarian cancer
JP2018019720A (ja) 前立腺癌における再発性の遺伝子融合物
JP2005503158A (ja) 色素生産性インサイチューハイブリダイゼーション方法、キットおよび組成物
JPWO2013133351A1 (ja) 新規ｆｇｆｒ３融合体
CN108192972A (zh) 用于乳腺癌转移的诊断、预后和治疗的方法
EP2094866B1 (en) Diagnosis and treatment of breast cancer
US20060194220A1 (en) Compositions and methods for detecting and treating tumors
EP2148932B1 (en) Sox11 expression in malignant lymphomas
JPWO2017122816A1 (ja) 新規融合体及びその検出法
EP2171094B1 (en) Mipol1-etv1 gene rearrangements
MX2012012735A (es) Deteccion y modulacion de formacion de vasos linfaticos mediados por la proteina slit y roundabount (robo), y usos de los mismos.
EP1829967A1 (en) Method of diagnosing malignant lymphoma and estimating the prognosis thereof
EP2125898B1 (en) Apcdd1 inhibitors for treating, diagnosing or detecting cancer
US20070128595A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
JP5467256B2 (ja) 消化器癌検出用血清腫瘍マーカー、消化器癌検出キット、および消化器癌検出方法
JP6806440B2 (ja) 新規融合体及びその検出法
HK40016239B (en) Mutations of the pik3ca gene in human cancers
HK40016239A (en) Mutations of the pik3ca gene in human cancers
US20110047634A1 (en) Methods and compositions for the diagnosis and treatment of acute lymphoblastic leukemia
WO2012097368A2 (en) Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
AU2007216790A1 (en) Methods and kits for diagnosing and treating B-cell chronic lymphocytic leukemia (B-CLL)

Legal Events

Date Code Title Description
FZDE Discontinued